Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomised, Two Part, Two Treatment Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Famotidine

Next Previous
Trial Profile

An Open-Label, Randomised, Two Part, Two Treatment Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Famotidine

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Savolitinib (Primary) ; Famotidine
  • Indications CNS cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 28 Jul 2021 Results assessing the effect of rifampicin, itraconazole and famotidine on savolitinib PK, and the effect of savolitinib on midazolam exposure from four studies (NCT04118842, NCT04121910, NCT04179071,NCT04187456) published in the British Journal of Clinical Pharmacology
  • 21 Apr 2021 Results of two open label studies (NCT04187456 and NCT04179071), presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics and International Transporter Consortium Workshop 4
  • 02 Jul 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top